摘要
目的研究托伐普坦联合桂哌齐特治疗急性心力衰竭患者的疗效及对患者血清可溶性生长刺激表达因子2(sST2)和血清心型脂肪酸结合蛋白(H-FABP)水平的影响。方法随机选取急性心力衰竭患者132例,按照随机数字表法分为观察组和对照组,每组66例。对照组给予桂哌齐特,观察组给予托伐普坦片联合桂哌齐特。治疗2周,比较2组患者的疗效、心功能、心衰指标、sST2及H-FABP水平。比较2组治疗期间不良反应发生率。结果治疗后,观察组有效率(92.42%)高于对照组(77.27%)(χ^(2)=9.650,P=0.002)。治疗后,观察组尿量、肾小球滤过率、左室舒张末期内径(LVEDD)和左室射血分数(LVEF)均高于对照组(P<0.05);观察组肌钙蛋白I(cTnI)、肌酸激酶同工酶(CK-MB)和血清N端-B型脑钠肽前体(NT-proBNP)、sST2和H-FABP水平均低于对照组(P<0.05)。2组患者不良反应发生率分别为1.52%、4.55%(χ^(2)=1.460,P=0.228)。结论托伐普坦联合桂哌齐特治疗急性心力衰竭具有良好的疗效,可有效改善患者的心功能、肾功能,减少患者心肌损伤,且安全性高。
Objective To study the efficacy of tolvaptan combined with guipazide in patients with acute heart failure and its effect on serum soluble growth stimulating factor 2(sST2)and heart type fatty acid binding protein(H-FABP).Methods 132 patients with acute heart failure were randomly divided into observation group and control group,with 66 cases in each group.The control group were given guipazide,and the observation group were given Tolvaptan Tablets combined with guipazide.The both groups were treated for 2 weeks.The curative effect,heart function,heart failure index,sST2 and H-FABP levels were compared between the 2 groups.The incidence of adverse reactions during treatment was compared between the 2 groups.Results After treatment,the effective rate of the observation group(92.42%)was higher than that of the control group(77.27%)(χ~2=9.650,P=0.002).After treatment,the urine volume,glomerular filtration rate,left ventricular end diastolic diameter(LVEDD)and left ventricular ejection fraction(LVEF)in the observation group were higher than those in the control group(P<0.05).Troponin I(cTnI),creatine kinase isozyme(CK-MB)and plasma N-terminal B-type brain natriuretic peptide precursor(NT-proBNP),sST2 and H-FABP in the observation group were lower than those in the control group(P<0.05).The incidence of adverse reactions in the 2 groups were 1.52%and 4.55%respectively(χ~2=1.460,P=0.228).Conclusion Tolvaptan combined with guipazide has a good effect intue treatment of acute heart failure,which can effectively improve the heart function,renal function,and reduce myocardial injury,with high safety.
作者
王广弟
郭照军
黄茂芹
廖煌
WANG Guangdi;GUO Zhaojun;HUANG Maoqin;LIAO Huang(The Second Ward of Cardiovascularlogy,the Second Affiliated Hospital of Hainan Medical University,Haikou 570311,China;Department of Cardiovascularlogy,the Second Affiliated Hospital of Hainan Medical University,Haikou 570311,China)
出处
《西北药学杂志》
CAS
2022年第4期131-134,共4页
Northwest Pharmaceutical Journal
基金
海南省自然科学基金面上项目(编号:818MS132)。
